Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type II Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

AHEPA University Hospital of Thessaloniki

Thessaloniki, 54454, Greece

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Type II diabetes mellitus
Poor glycemic control

Exclusion criteria

Heart failure
Renal disease
Liver disease
Cardiovascular event

Treatment and study plan

rosiglitazone

Drug

Primary outcomes

Cardiovascular risk factors alterations

Sponsors and collaborators

Lead sponsor

Aristotle University Of Thessaloniki

Other

Collaborators

University of Athens

Registry information

Important dates

Study start: 2005
Study completion: 2006
First posted: Mar 23, 2006
Registry last updated: Apr 4, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed